Omeros Corp
NASDAQ:OMER
Omeros Corp
Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 213 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, immunologic diseases and cancers. The Company’s lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and coronavirus (COVID-19). OMS906, the Company’s inhibitor of MASP-3, the alternative pathway of complement, is in a Phase 1 clinical trial.
Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 213 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, immunologic diseases and cancers. The Company’s lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and coronavirus (COVID-19). OMS906, the Company’s inhibitor of MASP-3, the alternative pathway of complement, is in a Phase 1 clinical trial.
Novo Nordisk Deal: Omeros entered a major asset deal with Novo Nordisk for its MASP-3 antibody Zaltenibart, valued up to $2.1 billion with $240 million upfront, expected to close this quarter.
Balance Sheet: The Novo deal will allow Omeros to pay off $67.1 million in secured loans and $17.1 million in 2026 notes, providing operating runway for over 12 months post-closing.
YARTEMLEA Approval: Lead product narsoplimab (YARTEMLEA) for TA-TMA has a December 26, 2025 FDA decision date; Omeros is launch-ready and expects no impact from the recent government shutdown.
Financial Results: Q3 net loss was $30.9 million ($0.47 per share), higher than last quarter due to an $8.8 million noncash derivative charge; adjusted net loss was $22.1 million.
Cash Position: Omeros ended Q3 with $36.1 million in cash and investments, and raised $20.3 million from a direct offering and $9 million from an ATM program.
Future Outlook: Operating expenses are expected to rise in Q4 due to YARTEMLEA launch costs; company targets cash flow positivity in 2027 if approvals proceed as planned.
